Dr Josep Tabernero speaks to ecancer about the final analysis of the phase III KRYSTAL-10 trial evaluating adagrasib plus cetuximab as second-line treatment for KRAS G12C-mutated metastatic colorectal cancer.

The study found that the chemotherapy-free combination did not significantly improve progression-free or overall survival compared with chemotherapy. However, it produced a higher objective response rate, including more complete responses, with manageable safety and no new safety signals.

Dr Tabernero discusses the clinical activity of the regimen and its potential role in previously treated patients.